Terminated NA INTERVENTIONAL 1-arm NCT01005875

Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma (RAD 0901)

RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

Sponsor: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Conditions Hepatocellular Carcinoma Liver Cancer

Interventions Sorafenib Stereotactic Body Radiotherapy (SBRT)

Updated 10 times since 2017 Last updated: Apr 3, 2017 Started: Nov 30, 2009 Primary completion: Dec 31, 2012 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.

Other terminated trials from Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

See all terminations from Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

Listed as NCT01005875, this NA trial focuses on Hepatocellular Carcinoma and Liver Cancer and remains terminated or withdrawn. Sponsored by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Dec 2021 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Dec 2021 [monthly]

Terminated NA
Nov 2020 — Jan 2021 [monthly]

Terminated NA

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Terminated NA
May 2018 — Jun 2018 [monthly]

Terminated NA
Aug 2017 — May 2018 [monthly]

Terminated NA
Feb 2017 — Aug 2017 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
University of Alabama at Birmingham

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States